Data-driven approach could help improve allocation of biomedical research resources

September 15, 2015, University of Chicago Medical Center

A new computational model developed by scientists from the University of Chicago could help improve the allocation of U.S. biomedical research resources. The tool, called the Research Opportunity Index (ROI), measures disparities between resources dedicated to a disease and its relative burden on society. ROI identifies diseases that receive a disproportionate share of biomedical resources, which represent opportunities for high-impact investment or for the realignment of existing resources. It is designed to provide an unbiased, data-driven framework to help scientific and political communities assess resource investment and identify unmet medical needs. ROI is described in the August issue of Nature Biotechnology.

"The misalignment of resources in biomedical research could be likened to poor budgeting of household finances," said senior study author Andrey Rzhetsky, PhD, professor of genetic medicine and senior fellow at the Institute for Genomics and Systems Biology at the University of Chicago. "It would be bad to spend all your money on food, for example, and have nothing for rent. Resources are finite and attention to each problem ideally should be proportional to the need."

The biomedical research community is increasingly faced with difficult choices when it comes to allocating finite resources, both human and financial. Meanwhile, there are few unbiased methods to determine how to focus resources for the best return on investment.

Rzhetsky and his colleagues addressed this problem by creating a mathematical framework called a Research Opportunity Index (ROI). It estimates the societal burden of 1,400 medical conditions in the U.S. over a 12-year timespan, based on frequency of diagnosis and insurance costs, as well as research publications, awarded grants and clinical trials for each condition. The index then calculates misalignments, allowing the team to create an "investment portfolio" of the resources dedicated to each disease, relative to its burden on the U.S. health care system.

The team found that , for example, stands out as a disease with higher dedicated resources than its relative societal burden. On the opposite end of the spectrum, Hashimoto's thyroiditis falls among the conditions with the most investment potential. The autoimmune disorder is the most common cause of hypothyroidism and occurs when the immune system attacks the thyroid gland, disrupting the body's balance of hormones. While it has nearly the same incidence among women as breast cancer, there were only 16 open clinical trials for Hashimoto's disease as of August 2015, according to a list on clinicaltrials.gov. Breast cancer had 2,205.

Rzhetsky and his colleagues acknowledge that the question of what makes a condition more deserving of funding than any other ailment is complex and multifaceted. But the team hopes this new tool can help the community decide on how best to allocate funds and other resources. By providing a framework based on unbiased quantitative analytics and big data, they hope to identify diseases that are high-impact and rewarding targets for additional investment.

"Some diseases stick in the public's attention," Rzhetsky said. "We have a distorted map of the frequency and importance of events from media and articles, and without special efforts to reconcile the reality, we are inherently biased."

The team are now working to incorporate other models of funding distribution into their index to account for additional variables. For example, the "trendy model," which supports investment for diseases with large emotional impact, suggests that even though this reduces funding for other diseases, there may still be benefits as basic science discoveries are added to the scientific and medical community.

"With the availability of more and more data analytics in health care, it's the right time to use data to direct the investments of drug discovery and biomedical research for the common good," said the study's first author, Lixia Yao, PhD, assistant professor at the University of North Carolina at Charlotte.

Explore further: Pneumonia investment doesn't match mortality burden

More information: "Health ROI as a measure of misalignment in biomedical needs and resources" Nature Biotechnology, 2015. DOI: 10.1038/nbt.3276

Related Stories

Pneumonia investment doesn't match mortality burden

July 15, 2015

UK investment in pneumonia research is lacking when compared to spending on influenza and tuberculosis, according to a new study by the University of Southampton and University College London (UCL).

US slipping as global leader in medical research

January 14, 2015

Once the undisputed center of global innovation in medicine, the U.S. is steadily losing ground to Asia and Europe and will, if trends continue, relinquish its leadership in the coming decade. That is the conclusion of an ...

Tool helps public health agencies prioritize health risks

July 31, 2015

Public health agencies across the globe are challenged with preventing the spread of chronic diseases while dealing with limited funds and devastating budget cuts. Now, a researcher at the University of Missouri has applied ...

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...

Recommended for you

Coffee-based colloids for direct solar absorption

March 22, 2019

Solar energy is one of the most promising resources to help reduce fossil fuel consumption and mitigate greenhouse gas emissions to power a sustainable future. Devices presently in use to convert solar energy into thermal ...

NASA instruments image fireball over Bering Sea

March 22, 2019

On Dec. 18, 2018, a large "fireball—the term used for exceptionally bright meteors that are visible over a wide area—exploded about 16 miles (26 kilometers) above the Bering Sea. The explosion unleashed an estimated 173 ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.